{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:45:52Z","timestamp":1792539952255,"version":"4.5.0"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2021,7,1]]},"DOI":"10.1001\/jamadermatol.2021.1570","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T18:21:03Z","timestamp":1622053263000},"page":"805","source":"Crossref","is-referenced-by-count":41,"title":["Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases"],"prefix":"10.1001","volume":"157","author":[{"given":"Maria C.","family":"Schneeweiss","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wyss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhu","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyn","family":"Chin","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology, George Washington University School of Medicine and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"doi210020r1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-0036-1579642","article-title":"Thrombosis in autoimmune diseases: a role for immunosuppressive treatments?","volume":"42","author":"Silvestri","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"doi210020r2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/jth.2012.10.issue-5","article-title":"Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study.","volume":"10","author":"Johannesdottir","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"10","key":"doi210020r3","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis.","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"doi210020r4","article-title":"Association of inflammatory skin diseases with venous thromboembolism in US adults.","author":"Shaheen","journal-title":"Arch Dermatol Res"},{"issue":"39","key":"doi210020r5","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","article-title":"Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study.","volume":"39","author":"Ogdie","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"doi210020r6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018125","article-title":"Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study.","volume":"6","author":"Ahlehoff","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"doi210020r7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.thromres.2014.06.021","article-title":"Increased risk of venous thromboembolism in patients with dermatomyositis\/polymyositis: a nationwide cohort study.","volume":"134","author":"Chung","year":"2014","journal-title":"Thromb Res"},{"issue":"7","key":"doi210020r8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/1753-0407.12631","article-title":"Longitudinal study of short-term corticosteroid use by working-age adults with diabetes mellitus: risks and mitigating factors.","volume":"10","author":"Rogers","year":"2018","journal-title":"J Diabetes"},{"issue":"4","key":"doi210020r9","doi-asserted-by":"publisher","first-page":"M11","DOI":"10.1530\/EJE-15-0198","article-title":"Adverse effects of glucocorticoids: coagulopathy.","volume":"173","author":"Coelho","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"doi210020r10","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"doi210020r11","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology.","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"doi210020r12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamafacial.2018.0331","article-title":"Risk of venous thromboembolism in patients with keratinocyte carcinoma.","volume":"20","author":"Rudy","year":"2018","journal-title":"JAMA Facial Plast Surg"},{"issue":"4","key":"doi210020r13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/1358863X15573839","article-title":"The validity of ICD codes coupled with imaging procedure codes for identifying acute venous thromboembolism using administrative data.","volume":"20","author":"Alotaibi","year":"2015","journal-title":"Vasc Med"},{"issue":"2","key":"doi210020r14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamainternmed.2019.5135","article-title":"Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism.","volume":"180","author":"Walker","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"4","key":"doi210020r15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.thromres.2015.01.012","article-title":"Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data.","volume":"135","author":"Sanfilippo","year":"2015","journal-title":"Thromb Res"},{"issue":"8","key":"doi210020r16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009960","article-title":"Chart validation of inpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTE) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database.","volume":"97","author":"Ammann","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"doi210020r17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/pds.2341","article-title":"A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data.","volume":"21","author":"Tamariz","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"doi210020r18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.1926","article-title":"A basic study design for expedited safety signal evaluation based on electronic healthcare data.","volume":"19","author":"Schneeweiss","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"doi210020r19","first-page":"I9","article-title":"Risk factors for venous thromboembolism.","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"issue":"12","key":"doi210020r20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models.","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"doi210020r21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"doi210020r22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies.","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"doi210020r23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"25","key":"doi210020r24","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"doi210020r25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Society Series B"},{"issue":"3","key":"doi210020r27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.v99.3","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare Databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"doi210020r28","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/art.v69.6","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study.","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"doi210020r29","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.","volume":"42","author":"Patorno","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"doi210020r30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3\u2014management and treatment with phototherapy and systemic agents.","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi210020r31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi210020r32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II\u2014topical, intralesional, and systemic medical management.","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi210020r33","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.2012.166.issue-5","article-title":"British Association of Dermatologists\u2019 guidelines for the management of alopecia areata: 2012.","volume":"166","author":"Messenger","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi210020r34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.v183.6","article-title":"The epidemiology of hidradenitis suppurativa.","volume":"183","author":"Ingram","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi210020r35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis.","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10247","key":"doi210020r36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis.","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"doi210020r37","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"doi210020r38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaad.2016.11.010","article-title":"Current and emerging treatments for vitiligo.","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9988","key":"doi210020r39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo.","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"doi210020r40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism.","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"doi210020r41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"issue":"1","key":"doi210020r42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","article-title":"Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.","volume":"117","author":"Cushman","year":"2004","journal-title":"Am J Med"},{"issue":"9","key":"doi210020r43","doi-asserted-by":"publisher","first-page":"832.e13","DOI":"10.1016\/j.amjmed.2013.02.024","article-title":"Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort.","volume":"126","author":"Tagalakis","year":"2013","journal-title":"Am J Med"},{"issue":"2","key":"doi210020r44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-04-0266","article-title":"The relationship between inflammation and venous thrombosis: a systematic review of clinical studies.","volume":"94","author":"Fox","year":"2005","journal-title":"Thromb Haemost"},{"key":"doi210020r45","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fped.2018.00142","article-title":"The role of inflammation in venous thromboembolism.","volume":"6","author":"Branchford","year":"2018","journal-title":"Front Pediatr"},{"issue":"23","key":"doi210020r46","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1056\/NEJM199006073222302","article-title":"Activation of coagulation after administration of tumor necrosis factor to normal subjects.","volume":"322","author":"van der Poll","year":"1990","journal-title":"N Engl J Med"},{"issue":"10","key":"doi210020r47","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"doi210020r48","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","article-title":"New and emerging systemic treatments for atopic dermatitis.","volume":"80","author":"Newsom","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"doi210020r49","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.3447","article-title":"Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.","volume":"22","author":"Asgari","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"doi210020r50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098024","article-title":"Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden\u2014a population-based register study.","volume":"9","author":"L\u00f6fvendahl","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"doi210020r51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjd.13041","article-title":"The validity of the diagnostic code for hidradenitis suppurativa in an electronic database.","volume":"171","author":"Kim","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi210020r52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4103\/ijt.ijt_67_20","article-title":"Validation of case identification for alopecia areata using International Classification of Diseases coding.","volume":"12","author":"Lavian","year":"2020","journal-title":"Int J Trichology"},{"issue":"7","key":"doi210020r53","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/all.2017.72.issue-7","article-title":"Validation of International Classification of Disease Ninth Revision codes for atopic dermatitis.","volume":"72","author":"Hsu","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"doi210020r55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.ede.0000147164.11879.b5","article-title":"Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction.","volume":"16","author":"Schneeweiss","year":"2005","journal-title":"Epidemiology"},{"key":"doi210020r54","volume-title":". Dermatology","author":"Bolognia","edition":"4th ed."},{"key":"doi210020r26","unstructured":"Aetion Inc. Aetion evidence platform. Software for real-world data analysis. 2020. Accessed February 1, 2021. http:\/\/aetion.com?"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2780050\/jamadermatology_schneeweiss_2021_oi_210020_1626722361.63103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T16:17:21Z","timestamp":1725121041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2780050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.1570","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}